KalVista Pharmaceuticals Future Growth
Future criteria checks 5/6
KalVista Pharmaceuticals is forecast to grow earnings and revenue by 61.3% and 52.4% per annum respectively while EPS is expected to grow by 63.5% per annum.
Key information
61.3%
Earnings growth rate
63.5%
EPS growth rate
| Biotechs earnings growth | 42.7% |
| Revenue growth rate | 52.4% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 04 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 4/30/2027 | 174 | -7 | -48 | 23 | 5 |
| 4/30/2026 | 80 | -109 | -141 | -93 | 7 |
| 4/30/2025 | 20 | -155 | -170 | -151 | 7 |
| 7/31/2024 | N/A | -142 | -103 | -103 | N/A |
| 4/30/2024 | N/A | -127 | -90 | -89 | N/A |
| 1/31/2024 | N/A | -108 | -97 | -97 | N/A |
| 10/31/2023 | N/A | -101 | -79 | -78 | N/A |
| 7/31/2023 | N/A | -95 | -80 | -79 | N/A |
| 4/30/2023 | N/A | -93 | -76 | -75 | N/A |
| 1/31/2023 | N/A | -91 | -81 | -79 | N/A |
| 10/31/2022 | N/A | -92 | -86 | -84 | N/A |
| 7/31/2022 | N/A | -89 | -85 | -83 | N/A |
| 4/30/2022 | N/A | -82 | -79 | -78 | N/A |
| 1/31/2022 | N/A | -73 | -63 | -62 | N/A |
| 10/31/2021 | N/A | -61 | -57 | -56 | N/A |
| 7/31/2021 | N/A | -52 | -45 | -44 | N/A |
| 4/30/2021 | N/A | -46 | -30 | -30 | N/A |
| 1/31/2021 | 4 | -38 | -32 | -32 | N/A |
| 10/31/2020 | 5 | -37 | -37 | -37 | N/A |
| 7/31/2020 | 9 | -33 | -37 | -37 | N/A |
| 4/30/2020 | 13 | -29 | -45 | -45 | N/A |
| 1/31/2020 | 12 | -31 | -43 | -43 | N/A |
| 10/31/2019 | 14 | -26 | -41 | -40 | N/A |
| 7/31/2019 | 16 | -23 | -42 | -41 | N/A |
| 4/30/2019 | 16 | -21 | -37 | -36 | N/A |
| 1/31/2019 | 18 | -13 | -34 | -32 | N/A |
| 10/31/2018 | 16 | -14 | 5 | 7 | N/A |
| 7/31/2018 | 12 | -16 | 7 | 9 | N/A |
| 4/30/2018 | 8 | -16 | N/A | 11 | N/A |
| 1/31/2018 | 4 | -19 | N/A | 14 | N/A |
| 10/31/2017 | 2 | -22 | N/A | -26 | N/A |
| 7/31/2017 | 1 | -21 | N/A | -23 | N/A |
| 4/30/2017 | 2 | -21 | N/A | -24 | N/A |
| 1/31/2017 | 2 | -23 | N/A | -23 | N/A |
| 10/31/2016 | 2 | -18 | N/A | -15 | N/A |
| 7/31/2016 | 2 | -18 | N/A | -15 | N/A |
| 4/30/2016 | 2 | -15 | N/A | -13 | N/A |
| 4/30/2015 | 2 | -9 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4XC1 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: 4XC1 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 4XC1 is expected to become profitable in the next 3 years.
Revenue vs Market: 4XC1's revenue (52.4% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 4XC1's revenue (52.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 4XC1's Return on Equity is forecast to be high in 3 years time